Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0086

Scientific exchange · Dr. Sven Abbott

05 Jun 2026 · Virtual · Dr. Sven Abbott, Policlinico Gemelli · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0086—

Capture insight from this engagement

Location: Policlinico Gemelli
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

Infusion-reaction management
Elderly / ECOG 2 patients

Scientific content used

VTX core scientific deck v3.2
irAE management guide

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with thoracic medical oncologist at Policlinico Gemelli. Discussed infusion-reaction management, elderly / ecog 2 patients.

Insights captured (1)

Capture insight

INS-0020Medium
Infusion-reaction management
Infusion-reaction management: interest in collaboration reported by thoracic medical oncologist (IT).
Outcome recorded

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 2
Depth of exchange: 4
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0086

Audit history (0)

All create, update and approval events for this record

No audit events in sample data